These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17450046)

  • 1. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
    Armenteros JL; Lewis JE; Davalos M
    J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):558-565. PubMed ID: 17450046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
    Farmer CA; Epstein JN; Findling RL; Gadow KD; Arnold LE; Kipp H; Kolko DJ; Butter E; Schneider J; Bukstein OG; McNamara NK; Molina BS; Aman MG
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):117-124. PubMed ID: 27348211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
    Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
    Findling RL; Townsend L; Brown NV; Arnold LE; Gadow KD; Kolko DJ; McNamara NK; Gary DS; Kaplin DB; Farmer CA; Kipp H; Williams C; Butter EM; Bukstein OG; Rice R; Buchan-Page K; Molina BS; Aman MG
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):52-65. PubMed ID: 28212067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
    Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
    J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
    Rundberg-Rivera EV; Townsend LD; Schneider J; Farmer CA; Molina BB; Findling RL; Gadow KD; Bukstein OG; Arnold LE; Kolko DJ; Buchan-Page KA; McNamara NK; Michel C; Austin A; Kipp H; Rice RR; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):225-33. PubMed ID: 25885012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
    Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
    Aman MG; Bukstein OG; Gadow KD; Arnold LE; Molina BS; McNamara NK; Rundberg-Rivera EV; Li X; Kipp H; Schneider J; Butter EM; Baker J; Sprafkin J; Rice RR; Bangalore SS; Farmer CA; Austin AB; Buchan-Page KA; Brown NV; Hurt EA; Grondhuis SN; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):47-60.e1. PubMed ID: 24342385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not just another antipsychotic-for-conduct-problems trial.
    Blader JC
    J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):17-20. PubMed ID: 24342382
    [No Abstract]   [Full Text] [Related]  

  • 14. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
    Gadow KD; Arnold LE; Molina BS; Findling RL; Bukstein OG; Brown NV; McNamara NK; Rundberg-Rivera EV; Li X; Kipp HL; Schneider J; Farmer CA; Baker JL; Sprafkin J; Rice RR; Bangalore SS; Butter EM; Buchan-Page KA; Hurt EA; Austin AB; Grondhuis SN; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):948-959.e1. PubMed ID: 25151418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.
    Correia Filho AG; Bodanese R; Silva TL; Alvares JP; Aman M; Rohde LA
    J Am Acad Child Adolesc Psychiatry; 2005 Aug; 44(8):748-55. PubMed ID: 16034276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB; Klorman R; Thatcher JE; Borgstedt AD
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
    Akhondzadeh S; Mohammadi MR; Khademi M
    BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.